Key insights from EBMT 2025, including trends in CAR-T, JACIE developments, and the growing demand for contingency services in cell therapy. Read Biovault’s perspective on what’s shaping the future of the field.
In 2023, Biovault worked alongside 6 NHS trusts to process 1,552 cellular therapy products and to release 753, making us a leading provider of PBSC services.
